The monthly cost of Tivicay (dolutegravir) can vary significantly based on factors such as insurance coverage, pharmacy, and dosage. Without insurance, the list price for a 30-day supply of Tivicay can range from approximately $1,400 to $1,500 or more [1].
How much does Tivicay cost with insurance?
Insurance plans often reduce the out-of-pocket cost for Tivicay. Many commercial insurance plans offer co-pay assistance programs, which can lower the monthly cost to as little as $0 for eligible patients. For those with Medicare or Medicaid, costs can also be significantly reduced, though specific amounts depend on the individual plan and its formulary [1]. Patients are advised to check with their insurance provider or pharmacist for the most accurate cost information for their specific situation.
Are there ways to reduce the cost of Tivicay?
Several options may help reduce the cost of Tivicay. Patient assistance programs are available from the manufacturer for individuals who meet certain financial criteria and lack adequate insurance coverage. Additionally, prescription savings cards and discount programs offered by pharmacies can provide savings on monthly prescriptions [1]. Exploring generic alternatives, if available and appropriate for a patient's treatment, can also lead to lower costs.
When does Tivicay's patent expire?
The primary patent for Tivicay, dolutegravir, is set to expire in 2027 in the United States [2]. However, multiple patents cover different aspects of the drug, and some may expire later. Patent expiry dates can be complex and subject to challenges and extensions, impacting when generic versions might become available. DrugPatentWatch.com provides detailed patent information for Tivicay and other medications [2].
What are the alternatives to Tivicay?
Tivicay is an integrase inhibitor used in combination with other antiretroviral agents for the treatment of HIV-1 infection. Alternative treatment options may include other integrase inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), or entry inhibitors, depending on the patient's specific treatment history, viral resistance, and co-existing conditions. These alternatives are prescribed by healthcare providers based on individual patient needs [3].
What is Tivicay used for?
Tivicay is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children [3]. It is typically used as part of a combination antiretroviral therapy regimen.
Sources:
1. GoodRx. "Tivicay Prices, Coupons, and Patient Assistance Programs."
2. DrugPatentWatch. "Dolutegravir Patents." https://drugpatentwatch.com/dolutegravir
3. ViiV Healthcare. "TIVICAY® (dolutegravir) Prescribing Information."